Dezhan HealthCare Co Ltd - Asset Resilience Ratio
Dezhan HealthCare Co Ltd (000813) has an Asset Resilience Ratio of 0.15% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Dezhan HealthCare Co Ltd short-term liquidity ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (1998–2025)
This chart shows how Dezhan HealthCare Co Ltd's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see balance sheet size of Dezhan HealthCare Co Ltd.
Liquid Assets Composition Over Time
This chart breaks down Dezhan HealthCare Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore 000813 long-term investments to assets to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥7.11 Million | 0.15% |
| Total Liquid Assets | CN¥7.11 Million | 0.15% |
Asset Resilience Insights
- Limited Liquidity: Dezhan HealthCare Co Ltd maintains only 0.15% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Dezhan HealthCare Co Ltd Industry Peers by Asset Resilience Ratio
Compare Dezhan HealthCare Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI |
Drug Manufacturers - Specialty & Generic | 1.54% |
|
Yunnan Baiyao Group Co Ltd
SHE:000538 |
Drug Manufacturers - Specialty & Generic | 8.38% |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317 |
Drug Manufacturers - Specialty & Generic | 6.62% |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK |
Drug Manufacturers - Specialty & Generic | 4.94% |
|
Harbin Gloria Pharmaceuticals
SHE:002437 |
Drug Manufacturers - Specialty & Generic | 9.04% |
|
Jiuzhitang Co Ltd
SHE:000989 |
Drug Manufacturers - Specialty & Generic | 7.86% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
|
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557 |
Drug Manufacturers - Specialty & Generic | 0.29% |
Annual Asset Resilience Ratio for Dezhan HealthCare Co Ltd (1998–2025)
The table below shows the annual Asset Resilience Ratio data for Dezhan HealthCare Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.21% | CN¥10.08 Million ≈ $1.48 Million |
CN¥4.87 Billion ≈ $712.93 Million |
-7.03pp |
| 2021-12-31 | 7.24% | CN¥418.41 Million ≈ $61.23 Million |
CN¥5.78 Billion ≈ $845.51 Million |
-9.96pp |
| 2020-12-31 | 17.20% | CN¥1.10 Billion ≈ $161.10 Million |
CN¥6.40 Billion ≈ $936.44 Million |
-18.09pp |
| 2019-12-31 | 35.29% | CN¥2.09 Billion ≈ $306.13 Million |
CN¥5.93 Billion ≈ $867.42 Million |
+27.52pp |
| 2018-12-31 | 7.77% | CN¥460.00 Million ≈ $67.31 Million |
CN¥5.92 Billion ≈ $866.52 Million |
+2.71pp |
| 2017-12-31 | 5.06% | CN¥260.00 Million ≈ $38.05 Million |
CN¥5.14 Billion ≈ $751.99 Million |
-0.54pp |
| 2016-12-31 | 5.60% | CN¥220.00 Million ≈ $32.19 Million |
CN¥3.93 Billion ≈ $574.63 Million |
+0.53pp |
| 2015-12-31 | 5.07% | CN¥100.00 Million ≈ $14.63 Million |
CN¥1.97 Billion ≈ $288.60 Million |
+5.05pp |
| 2005-12-31 | 0.03% | CN¥150.00K ≈ $21.95K |
CN¥597.31 Million ≈ $87.41 Million |
0.00pp |
| 2004-12-31 | 0.03% | CN¥199.06K ≈ $29.13K |
CN¥727.81 Million ≈ $106.50 Million |
-5.12pp |
| 2003-12-31 | 5.15% | CN¥54.37 Million ≈ $7.96 Million |
CN¥1.06 Billion ≈ $154.45 Million |
+2.43pp |
| 2002-12-31 | 2.72% | CN¥33.32 Million ≈ $4.88 Million |
CN¥1.22 Billion ≈ $179.14 Million |
-1.95pp |
| 2001-12-31 | 4.67% | CN¥56.87 Million ≈ $8.32 Million |
CN¥1.22 Billion ≈ $178.11 Million |
-5.68pp |
| 2000-12-31 | 10.35% | CN¥140.54 Million ≈ $20.57 Million |
CN¥1.36 Billion ≈ $198.62 Million |
+7.96pp |
| 1998-12-31 | 2.39% | CN¥27.00 Million ≈ $3.95 Million |
CN¥1.13 Billion ≈ $165.10 Million |
-- |
About Dezhan HealthCare Co Ltd
Dezhan Healthcare Company Limited engages in the research and development, manufacture, and sale of cardiovascular and cerebrovascular drugs in the People's Republic of China. The company offers atorvastatin calcium tablets, amlodipine-atorvastatin calcium tablets, warfarin sodium tablets, trimetazidine hydrochloride tablets, amiodarone hydrochloride tablets, as well as other drugs, including fam… Read more